ModelEdge

Chromocell Therapeutics

Filing Type	8-K
Filing Date	7/1/2025
Updated	7/2/25, 3:22 PM

Filing

Earnings Release

Exhibits

8-KMaterial Contracts, Completing Asset Acquisition or Sale, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregistered Sales of Equity Securities, Material Modifications to Rights of Security Holders, Change in Company Ownership, Changes in Board, Management or Compensation, Amendments to Articles of Incorporation o

EX-2.2EXHIBIT 2.2

EX-3.1EXHIBIT 3.1

EX-3.2EXHIBIT 3.2

EX-3.3EXHIBIT 3.3

EX-3.4EXHIBIT 3.4

EX-10.6EXHIBIT 10.6

EX-10.7EXHIBIT 10.7

EX-10.8EXHIBIT 10.8

EX-10.9EXHIBIT 10.9

EX-10.10EXHIBIT 10.10

EX-10.11EXHIBIT 10.11

EX-10.12EXHIBIT 10.12

EX-10.13EXHIBIT 10.13

EX-10.14EXHIBIT 10.14

EX-10.15EXHIBIT 10.15

EX-10.16EXHIBIT 10.16

EX-10.17EXHIBIT 10.17

EX-10.18EXHIBIT 10.18

EX-10.19EXHIBIT 10.19

EX-10.20EXHIBIT 10.20

EX-10.21EXHIBIT 10.21

EX-99.1Material Contracts, Completing Asset Acquisition or Sale, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregistered Sales of Equity Securities, Material Modifications to Rights of Security Holders, Change in Company Ownership, Changes in Board, Management or Compensation, Amendments to Articles of Incorporation o

EX-99.2Material Contracts, Completing Asset Acquisition or Sale, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregistered Sales of Equity Securities, Material Modifications to Rights of Security Holders, Change in Company Ownership, Changes in Board, Management or Compensation, Amendments to Articles of Incorporation o